Queens Hospital of Barking, Havering and Redbridge University Hospitals NHS Trust
Project Name: Queens Hospital, MPN Nurse Led Service Development Project. Project period: 27 months
Joint working project summary: The aim of the Joint Working Project (JWP) will be to develop a new Clinical Nurse Specialist (“CNS”) Myeloproliferative Neoplasm (“MPN”) clinic service to assess and identify MPN patients that may need referral to a Consultant clinic for a treatment review. There will also be a strong focus on building relationships with patients for effective communication and sharing patient support information, along with improving the quality of care and patient satisfaction. The new clinic service will allow the Consultants more time to concentrate on complex cases and to see more patients in need of a treatment review. In turn, this will increase the activity of the overall Queens Haematology MPN clinics and provide evidence of the long term financial sustainability of the service after the JWP comes to a conclusion.
The JWP will have an initial duration of 15 months, starting by the end of June 2016; at 15 months from inception, the JWP will be subject to review of its progression and subject to the JWP meeting the milestones as agreed, the parties will enter negotiations on whether to extend their collaboration, and on which terms, within the Joint Working framework for an additional period of 12 months. The NHS team and Novartis will form a project steering group (“PSG”) to initiate, review and measure the impact of this service, with the results included in a JWP summary report and a business case aimed at supporting funding the new service once the JWP comes to an end.
Expected patient outcomes for this project: A new CNS led clinic service in the Queens Haematology department to identify MPN patients that may require a treatment review and to improve MPN patient care using the following assessments:
• All Myelofibrosis and Polycythaemia Vera patients to receive an MPN10 symptom score assessment upon arrival in the new CNS clinic and at 6 monthly intervals.
• All Chronic Myeloid Leukaemia (“CML”) Tyrosine Kinase Inhibitor patients to receive a Cardiovascular (“C.V”) risk assessment, using the Novartis C.V. risk assessment toolkit upon arrival in the new CNS clinic and at 6 monthly intervals.
• Improve the average MPN patient satisfaction results at 12 and 24 months compared to the start of the CNS clinics via roll-out at clinic inception of a validated Queens Haematology department questionnaire.
• A new Queens Haematology department CML treatment review audit toolkit to collect and assess various clinical parameters from the new clinic service to inform clinical decisions of CML patients.
Start Date and Duration: June 2016 – September 2018
ONC16-C013 March 2016
Buckinghamshire Healthcare NHS Trust
Project name: Expanding and redesigning a more efficient eye service: reconfigurating macular service at Amersham Hospital Project period: 16 months (Start date: June 2016)
Joint working project summary The principal aim of this joint working project is to provide a one-stop macular service for patients at Buckinghamshire Healthcare NHS Trust which offers assessment and treatment on the same day.
By reconfiguring the current service at Amersham Hospital to create 3 new clinic rooms, 2 scanning rooms, 1 vision bay and 1 injection room, wet age related macular degeneration (wAMD) patients will be seen and treated in dedicated clinics.
The additional capacity means that new clinics will also be created at the Trust’s other sites at Stoke Mandeville and Wycombe General Hospital. This will help to ensure that referred patients are seen within the appropriate timescales and follow a standardised clinical treatment pathway.
Expected patient outcomes for this joint working project It is expected that the new wAMD clinics will provide consistent care to the relevant patient population and improve patients’ outcomes. Specifically, the following outcomes are expected:
• One-stop service is available to 90% of all follow-up patients • 90% of patients to be assessed within 1-2 weeks of referral • 90% of patients to receive treatment within 1 week of diagnosis • 90% of patients will have a follow-up within the date range requested by consultant or treating healthcare professional
OPT16-C049 July 2016
The Christie NHS Foundation Trust
Project Name: The Christie NHS Foundation Trust (The Christie) Renal Cell Carcinoma (RCC) Service development. Project period: 24 months
Joint working project summary: The collaborative approach with Novartis within the remit of a partnership project scheme will support the development of the Christie NHS Foundation Trust (The Christie) Renal Cell Carcinoma (RCC) Service development.
This development will see patients appropriately referred into the Christie RCC service from across the Greater Manchester Specialist Clinical Network and those patients referred into the service outside of GMSCN. These patients will follow a defined patient pathway where they will be stratified into different models of care depending on their needs.
The Christie RCC Team will ensure all members are upskilled in new developments, disease area and current patient management and treatments to become a center of excellence for the treatment of RCC.
All RCC Patients will be educated on their disease and treatment options providing holistic support to ensure optimal treatment management.
Our objective is to develop a sustainable Greater Manchester Clinical Network (GMCN) Advanced RCC service within The Christie NHS Foundation Trust by:
Ensuring equitable access and service for RCC patients across the GMCN and those patients referred in from outside the GMCN
Improving patient care by stratifying patients into different models of care that better reflect the patient needs. Enhancing patient experience by providing a patient key worker to educate patients on their disease, treatment choices, outcomes and goals;
Educating the RCC team in disease area, treatments and new developments to ensure the service becomes a center of excellence for the treatment of RCC.
Capturing and using project service data to demonstrate the service is benefitting patients and that the service is financially sustainable to The Christie NHS Foundation Trust
Expected patient outcomes for this project:
Outcome 1: Deliver an improved, equitable and accessible Advanced RCC Service across Greater Manchester Clinical Network and for patients referred in from and out of region with improved quality of care
Outcome 2: Improve patient care, experience and satisfaction by developing a service that is patient-centric and focussed on the individual needs and requirements of the patients.
Outcome 3: Educate the Advanced RCC team to become a high performing team providing excellent quality care
Outcome 4: Demonstrate service sustainability to The Christie NHS Foundation NHS Trust by working with Novartis to provide an anonymized annual report
Financial Contribution: This will be a 2 year project were both parties will review achievement of year 1 milestones & outcomes in month 12. It will then be decided if the project will continue into year 2 with agreed year 2 milestones with tactical plan and expected outcomes and the contract extended for a further 12 months.
Start Date: June 2016 – May 2018 VOR16-C115 June 2016